Xifaxan 2019 U.S. PROMOTIONAL AUDIT REPORT

Published July 2020 • 21 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Xifaxan through reportable promotional activity in 2019 and how does this compare to its peer set in the Hepatic Encephalopathy, Irritable Bowel Syndrome, and Traveler’s Diarrhea markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Salix’s depth of coverage vary within key specialties (e.g., Family Medicine, Internal Medicine, and Gastroenterology) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Xifaxan throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Xifaxan in 2019?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
• Over 104,000 paid interactions across 26,500 physicians made on behalf of Xifaxan were carefully examined to support our analysis. In addition, interaction data from 5 peer products (e.g. Amitiza, Donnatal, Linzess, Trulance, and Viberzi ) was leveraged to provide benchmarking and market insights.